Tesamorelin 3ml 8mg/ml

8 mg/ml | 3 ml

Growth Hormone Support • Metabolic Health • Body Composition

Tesamorelin is a synthetic analogue of growth hormone-releasing factor (GHRF/GHRH). It acts on GHRF receptors and stimulates the pituitary to release endogenous growth hormone, subsequently increasing levels of IGF-1 and IGFBP-3.

Tesamorelin has been extensively studied for its effects on visceral adipose tissue and body composition, with clinical research demonstrating reductions in visceral abdominal fat in appropriately selected patients.

How Does Tesamorelin Work?

Tesamorelin mimics the activity of naturally occurring growth hormone-releasing hormone. By stimulating GHRF receptors, it promotes the body's own pulsatile growth-hormone secretion rather than directly supplying growth hormone.

Growth hormone has multiple physiological effects involving tissues such as muscle, bone, liver and adipose tissue, with some effects mediated through IGF-1.

Research & Clinical Applications

Tesamorelin has been investigated in relation to:

Visceral abdominal fat – clinical trials have demonstrated reductions in visceral adipose tissue in adults with HIV-associated lipodystrophy.
Body composition – studies have evaluated changes in visceral fat, abdominal fat distribution and lean body mass.
Growth-hormone signalling – tesamorelin stimulates endogenous growth-hormone secretion and increases IGF-1.
Metabolic parameters – clinical studies have investigated changes in triglycerides and other metabolic markers alongside reductions in visceral fat.
Product Information
Product: Tesamorelin
Volume: 3 ml
Strength: 8 mg/ml
Format: Peptide formulation
Administration: Subcutaneous, as prescribed
Professional Guidance

Tesamorelin should be used under the supervision of a qualified healthcare professional. PeptideClinics states that its treatment programmes involve medical assessment and doctor review before products are prescribed and supplied.

The appropriate dose and administration schedule for your specific 8 mg/ml formulation should be determined by the prescribing doctor rather than transferred directly from another tesamorelin formulation, as approved formulations can differ in concentration, reconstitution and dosing instructions.

Important Information

Tesamorelin affects the growth-hormone/IGF-1 axis and is not appropriate for everyone. The approved labeling includes important contraindications and warnings, including active malignancy and certain disorders involving the hypothalamic-pituitary axis. It can also affect glucose metabolism and IGF-1 levels.

Tesamorelin is not approved as a general weight-loss treatment. Its established indication is reduction of excess abdominal fat in adults with HIV-associated lipodystrophy.

This product description is intended for informational purposes and does not replace personalised medical advice.

PeptideClinics South Africa
Be The Best You